Oncolytics Biotech Inc ONCY

ONCY pelareorep + CD3 bispecific antibody true-killer combo

[Noteable]

.... a true tumor-killer combo that would not be effective without each other.

Both bispecific T-cell engagers and oncolytic viruses are promising cancer therapies, but the new research demonstrates that combining the two approaches could work even better. The researchers first administered oncolytic reovirus to both syngeneic murine and humanized tumor models, then injected the CD3ε-bispecific antibodies. The combined treatment induced strong tumor regression and prolonged survival compared to each treatment option individually.

Preconditioning the tumor microenvironment with oncolytic reovirus resulted in the activation of immunologically cold tumors, explained the researchers. This in turn led to more successful engagement of bispecific antibodies, causing tumor cell death.

https://absoluteantibody.com/general/using-bispecific-antibody-reagents-to-further-research/

[Noteable]

ESMO 2022 - Regeneron has introduced a "plug and play" oncology strategy to improve checkpoint inhibitor treatments with combination therapies – centered around their PD-1 immune checkpoint inhibitor Libtayo. In a webcast, David Weinreich, M.D., Regeneron’s EVP, global clinical development, noted four approaches: CD3 bispecifics, dubbed Signal 1; CD28 bispecifics, named Signal 2

[Noteable]

Reovirus + CD3 bispecific combination .... "a true tumor-killer combo that would not be effective without each other." according to the investigators who undertook the bispecific combination study.

[Noteable]

Currently Roche's CD3 bispecific for lymphoma drug Lunsumio (monsunetuzumab) is an off-the-shelf antibody that has been given conditional approval in Europe and will be a contender with CAR-T therapy in liquid cancers. Lunsumio can be used alone or in combination with its checkpoint inhibitor atezolizumab. Pfizer's bispecific elranatamab is an investigational B-cell maturation antigen

[Noteable]

Activating the Tumor Microenvironment Both bispecific T-cell engagers and oncolytic viruses are promising cancer therapies, but the new research demonstrates that combining the two approaches could work even better. The researchers first administered oncolytic reovirus to both syngeneic murine and humanized tumor models, then injected the CD3ε-bispecific antibodies. The combined treatment

[westcoast1000]

Another important post. Thanks Noteable. Pela is a weapon to enhance Immune response so these biospecific antibodies can really work. Let it happen, so we can save lives. 

[Noteable]

Repost:  .... a true tumor-killer combo that would not be effective without each other. Both bispecific T-cell engagers and oncolytic viruses are promising cancer therapies, but the new research demonstrates that combining the two approaches could work even better. The researchers first administered oncolytic reovirus to both syngeneic murine and humanized tumor models, then injected

[Noteable]

December 06, 2022 - Micro-cap Summit Therapeutics is betting $5 billion, including $500 million in upfront cash, for Akesio’s bispecific antibody. The deal is one of the largest deals in 2022 and in recent memory, reminiscent of AstraZeneca’s potential $6 billion licensing pact for Daichii Sankyo’s TROP2 antibody-drug conjugate disclosed in 2020.

[Noteable]

August 11, 2023 -   FDA Approves J&J's Second Multiple Myeloma Bispecific Antibody  Johnson & Johnson took the fast track for its latest cancer drug. J&J’s  subsidiary Janssen Pharmaceutical announced Thursday its bispecific antibody has won accelerated approval from the FDA for relapsed or refractory multiple myeloma.  J&J

[Noteable]

Repost from August 11, 2023 - FDA Approves J&J's Second Multiple Myeloma Bispecific Antibody    Johnson & Johnson took the fast track for its latest cancer drug. J&J’s subsidiary Janssen Pharmaceutical announced Thursday its bispecific antibody has won accelerated approval from the FDA for relapsed or refractory multiple myeloma. 

[Noteable]

https://www.fiercepharma.com/pharma/jj-expands-multiple-myeloma-arsenal-fda-approval-first-class-talvey

[Noteable]

November 03, 2022 - Pfizer's Elranatamab, a B-cell maturation antigen (BCMA)-CD3-targeted bispecific antibody (BsAb), received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of people with relapsed or refractory multiple myeloma (RRMM). BsAbs are a novel form of cancer immunotherapy that bind to and engage two different

[jimsenior]

A layman's look at ONC & Multiple Myeloma. In numerical order from clinical trials.gov. 6. Ambush - Not yet recruiting. Adding Keytruda. 7. Celgene Trial Status Unknown, this would have fallen under the aegis of BMS presumably. 10. NCI Reolysin Complete 11. NCI/ONC Reovirus and Bortezomib. This trial presumably led to AMBUSH in which Keytruda will be added. 12. NCI Carfilzomib. Active

[Noteable]

In June 2022 Roche presented data from its T-cell engaging bispecific antibody development programmes at European Hematooty Association (EHA) 2022 congress including their investigational medicines cevostamab and RG6234 in relapsed or refractory multiple myeloma (RRMM). Along with the recent work in demonstrating that pelareorep + CD3 bispecific antibody is a true-killer combo, in 2020

[Noteable]

Should read ... European Hematology Association (EHA) 2022 congress Furthermore Groeneveldt et al. (Leiden University Medical Centre) stated in their findings that ONCY's pelareorep can be used intratumorally or intravenously when combining it with a CD3 bispecific, in prefacing their conclusion below: "Reovirus as a preconditioning regimen performed significantly better than

[Noteable]

In November 2022, Pfizer announced elranatamab received Breakthrough Therapy Designation from the Food and Drug Administration (FDA) for the treatment of RRMM. Elranatamab has also been granted Orphan Drug Designation by the FDA and the European Medicines Agency (EMA) for the treatment of MM. The FDA and EMA have granted elranatamab Fast Track Designation and the PRIME scheme, respectively, for

[Noteable]

December 12, 2022 - " On the heels of its FDA submission, Johnson & Johnson is unveiling results used to woo regulators on its bispecific antibody in multiple myeloma patients in dire need of successful treatment.    The new phase 2 data, released Monday at the American Society of Hematology annual meeting, showed that among patients who received a median of

[Noteable]

Repost: ... a true tumor-killer combo that would not be effective without each other. Both bispecific T-cell engagers and oncolytic viruses are promising cancer therapies, but the new research demonstrates that combining the two approaches could work even better. The researchers first administered oncolytic reovirus to both syngeneic murine and humanized tumor models, then injected the

[Noteable]

December 09, 2022 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for talquetamab for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). Talquetamab is an investigational, off-the-shelf (ready to use), bispecific T-cell engager

[Noteable]

J&J's Talquetamab, had been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) in June 2022 for hard-to-treat multiple myeloma. The FDA awards breakthrough therapy designation to accelerate the development of investigational treatments for serious or life-threatening conditions. It is based on preliminary clinical evidence showing a therapy’s

[Noteable]

December 12, 2022 - Pfizer today announced 10.4 month follow-up data from the pivotal Phase 2 MagnetisMM-3 clinical trial suggesting elranatamab, a B-cell maturation antigen (BCMA)-CD3-targeted bispecific antibody (BsAb), is efficacious and has a manageable safety profile in patients with relapsed or refractory multiple myeloma (RRMM) in a heavily pretreated population, who have received at

[Noteable]

Repost (2): another reason for Big Pharma's eagerness in ONCY's pelareorep ... a true tumor-killer combo that would not be effective without each other. Both bispecific T-cell engagers and oncolytic viruses are promising cancer therapies, but the new research demonstrates that combining the two approaches could work even better. The researchers first administered oncolytic

[Noteable]

Preconditioning the tumor microenvironment with oncolytic reovirus resulted in the activation of immunologically cold tumors, explained the researchers. This in turn led to more successful engagement of bispecific antibodies, causing tumor cell death. https://absoluteantibody.com/general/using-bispecific-antibody-reagents-to-further-research/ ONCY's oncolytic virus facilitates CD3 binding

[Noteable]

Roche and Pfizer are developing CD3 bispecifics. Currently Roche's CD3 bispecific for lymphoma drug Lunsumio (monsunetuzumab) is an off-the-shelf antibody that has been given conditional approval in Europe and will be a contender with CAR-T therapy in liquid cancers. Lunsumio can be used alone or in combination with its checkpoint inhibitor atezolizumab. Pfizer's bispecific elranatamab

[Noteable]

Johnson & Johnson's JNJ-8902 — a CD3 x TMEFF2 bispecific  - appears to have been retired. TMEFF2 is a transmembrane protein with EGF which was speculated to be a tumor immuosuppressor - which ONCY's pelareorep has demonstrated as capable of achieving in ONCY's AWARE-1 study and now potentially enhancing as a bispecific with a CD3 targeted antibody. https://endpts.com/jj

[Noteable]

January 2023 - The Cancer Journal - "The Impact of Precision Medicine in Oncology - Immuno-Oncology" -  "Cancer treatment has dramatically changed over the last decade with the development of immunotherapy. Therapies including immune cytokines, immune checkpoint inhibition, intratumoral therapies, and cellular therapies are already widely used in the oncology clinic.

[Noteable]

June 15, 2023 - The FDA has granted an accelerated approval to Roche’s Columvi, or glofitamab - a D20xCD3 bispecific T-cell engager, to treat diffuse large B-cell lymphoma (DLBCL) or large B-cell lymphoma arising from follicular lymphoma in patients who’ve tried at least two prior lines of systemic therapy. In the phase 2 trial that supported Columvi’s approval, 68% of

[Noteable]

August 23, 2024 -  Bispecific Antibody Drug Conjugates As Cancer Therapy https://www.biospace.com/press-releases/bispecific-antibody-drug-conjugates-as-cancer-therapy Roche and Pfizer are developing CD3 bispecifics. Currently Roche's CD3 bispecific for lymphoma drug Lunsumio (monsunetuzumab) is an off-the-shelf antibody that has been given conditional approval in Europe and will

[Noteable]

August 27, 2024 - Bispecific T-cell engagers (BiTEs) are designed to link T-cells to cancer cells by binding to the CD3 receptor on T-cells and a specific antigen on cancer cells. This close proximity induces T-cell activation and the release of cytotoxic molecules, leading to the targeted destruction of cancer cells. This mechanism has been particularly successful in treating certain types of

[13X2413]

August 27, 2024 - Down another cent. 

[Peladawn]

Kamala now going to finally honor voters with a so-called "live" interview to prove how "transparent" she is....except,  uhhh....the interview will not be live....she has agreed to do a pre-recorded interview, so they can edit out all of her fumbles, and cackles, and outright stupidity.....oh yeah, and of course she won't be doing the "live" interview alone..

[Peladawn]

....and now she's telling all her loyal little useful idiots how she's going build the wall (that she just spent the last 4 years insulting Trump about).....and all the little useful idiots are cheering and saying, "see!....look how tough Queen Kamala is going to be on illegal immigration.....yaaaaaaaah!.....she's going to make such a a strong president!......yaaaaaaaah!

[Azzak34]

I think this is what a nervous breakdown looks like. 

[Peladawn]

No Azzak....this is what a liar looks like that is willing to say or do ANYTHING to fulfill her and her party's lust for power.

[Peladawn]

What a shame that you and so many others are so brainwashed that you can't see it.

[Azzak34]

Wait, politicians lie and promise things they're never actually going to do when they get into office? 

[Peladawn]

Yes Azzak, most do....but your leftwing-brainwashed little mind will never see that Trump fulfilled most of the promises he made when he was elected in 2016......you know why?.....because he made promises that were actually based in reality, that why.....but the leftwing, Trump-hating media refused to  admit any of the things Trump did for his country

[Peladawn]

.....and inflation was at 1.4% when Trump was in office, not 20%....and gas was selling at an average of 1.64 a gallon, not 3.54.....go ahead and come up with another snide remark and try to deny that

[Srxman2001]

Like build a wall and have mexico pay for it, like repeal obama care on day one. lol.   your lucky a global pandemic came around so you can ride he made gas cheaper.  please dont go as far as drink the coolaide.  pn second thought, go ahead

[CaseyL]

Biden and Harris did nothing, nearing the end they ramped up efferts on the border. It still needs more work. It was never finished. Too many people were killed from these illegal immigrants. 

[CaseyL]

New York is bing rampaged with comple store destruction and theft. All immigrants. 

[CaseyL]

https://www.youtube.com/watch?v=sLHRgAdQwqg

[Azzak34]

It's your guys fault he's going to lose this. All you had to do was buy more trump bibles or trump sneakers or trump trading cards! You didn't grift hard enough.  Whoever wins is going to wreck the place, there's no getting around it. 

[CaseyL]

You're an idiot on either side. 

[Peladawn]

Srxman....Trump forced Mexico through tariffs to agree to Title 42.....remember that?...the remain in Mexico policy?....where all illegal immigrants had to remain in Mexico while they were PROPERLY VETTED and to await their court appearance to apply for a proper asylum decision Title 42 was equal to a virtual wall, because it prevented criminals and terrorists from simply pouring into the country

[m00nsh0ts]

This post has been removed in accordance with Community Policy

[Noteable]

August 21, 2024 - Merck USA (MSD) acquires a single Phase 1 CD3xCD19-targeting T-cell-engager bispecific antibody designed to target B cells for elimination by T cells for US$ 1.3 Billion.  https://www.biopharminternational.com/view/merck-plans-to-acquire-investigational-bispecific-antibody-from-curon-biopharmaceutical-in-1-3-billion-deal

[Noteable]

New bioconjugates (i.e. bispecifics) could effectively pair ONCY's reovirus, with different polysaccharides resulting in increased trafficking tof revirus to the tumor cell surface and further facilitate pushing biologics and cancer therapy into the next generation of personalized/precision medicine that reovirus brings to the treatment of various cancers, including metastatic breast

[13X2413]

Previous fire pit bull sessions haven't resulted in any positive action. Hence the need for more chats. Who keeps listening to their dog and pony shows?

[Noteable]

A more recently developed, alternative method to produce polysaccharide–protein conjugates, termed bioconjugation, has been shown to simplify conjugate vaccine production and has been adopted by major pharmaceutical companies, thus making ONCY's pelareorep a very attractive biologic agent to be linked to form a pelareorep-CD3 bispecific bioconjugate for the effective treatment of various

[Noteable]

CD3 protiens have become a hot target for bispecific antibodies. T cell bispecific antibodies (TCBs) are molecules that are engineered to include binding sites to the T cell receptor (TCR) and to tumor-associated or tumor-specific antigens within a single entity. One of the most widely studied TCBs in cancer immunotherapy is CD3, a molecule that has the function of stabilizing TCR structure and

[Noteable]

Should read: CD3 proteins ... have become a hot target for bispecific antibodies.

[Noteable]

My oh my .. a lot of smack has suddenly appeared on this message board. Could it be that certain entities are feeling increasingly threatened ? 

[13X2413]

Interesting way to spin a lot of frustrated bag holders as the stock drops to $1.28. Not far from a 12 month low. You think we should be positive about how things are going?

[Noteable]

Chinese owned Phase 1 TiLs technology therapy in-licensed by Instilbio currently trading at US$46 per share, again outlining the undervaluation of ONCY  https://ir.instilbio.com/stock-information/stock-quote-chart

[venture009]

With a market cap of 302 million ONC would have a share value of approximately $4 / share.

[Noteable]

And Phase 3  Summit Therapeutics whose Chinese owned and trialed bispecific, Ivonescimab, [an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA) ]  currently has a market cap of US $ 19.5 Billion. Again illustrating ONCY 's undervaluation.

[CaseyL]

By the looks, they have six phase 3 trials with a management that did not run the company in the ground. I think our current share price/value is about right. ONCY's management is a huge disappointment. 

[Noteable]

Having Phase 3 trials run in China do not equate to trials run in the US due to the lack of equivalent rigor and subsequently have nil opportunities for approval in the US or the EU. 

[Quentin30]

Agree, but they can run them for he chinese population... AN also have rights in other SE Asian markets. Phase III triggers milestone payments to ONCY... if AN does jack, then that's exactly what ONCY gets... so what does this partnership mean...    yup Jack.

[Noteable]

Summit Therapeutics US$19.5 Billion market cap is bizzare since their Phaswe 3 clinical trials have not been conducted in the United States and while their drug was a PD-1 + VEGF inhibitior vs. keytruda - the Phase 3 trials were not run against keytruda + the VEGF Avastin and have not reported on overall survival. So while Summitt Therapeutics may run clinical trials in the United States, Summit

[Buckhenry]

"Accelerated approval " in April... and it's now September.... hmmm

[Noteable]

Listen to the HC Wainwight & Co.  Global Healthcare Conference fireside chat to understand why an extended OS reporting was more beneficial beyond 24 months rather at 2 years or earlier. You obvious didn't choose to listen.

[laroplex]

Not sure how many times i mentioned this to ya Noteable....It is FANTASTIC and Noble of you  to take time to crank  sme excellent info for all of us...All facts that seems to fit the ongoing picture with ONC....Will it be worth it...You bet....Wake up one morning soon to Halt...."hold On it's Coming"....GLTA

[fasttrack5]

Posted on LinkedIn  Our IND-213 study showed that combining #pelareorep with #paclitaxel nearly doubled overall survival in HR+/HER2- metastatic #BreastCancer patients. This promising data has the potential to accelerate access to patients in need. Learn more: https://lnkd.in/g84Sunm7 #BreastCancerResearch #biotech #immunotherapy #CancerResearch #oncology #pela Just Sayin:)

[venture009]

For years we have been reading about all the positives and potential regarding pela on sites like this one and yet for years infleuential analyst have ignored this potential. Why is this happening? Can anyone provide a logical explanation for why analyst don't recognize the potential of pela. Because without this exposure it is going to be difficult to get any traction.The reason analysts are

[Noteable]

Analyst Firms Making Recommendations CANACCORD GENUI CANTOR FITZGERA H C WAINWRIGHT LEEDE FINANCIAL MAXIM GROUP,LLC RBC CAPITAL   Analyst Price Targets Consensus    $5.21 Based on analysts offering 12 month price targets for ONCY in the last 3 months. The average price target

[venture009]

Notable I watch BNN, CNBC and Fox Business and listened to a number of biotech analysts promoting companies they feel have the potential and yet not one have mentioned ONC. This includes RBC so they may be watching but they're not promoting with any enthusiasm.  Plus the sp estimates have never come close and lack of promotion is one reason.

[Noteable]

Neither BNN or CNBC or Fox Business mentioned Summit Therapeutics before it hit US$ 19.5 Billion in market cap - which since reached US$23.5 Billion in market cap on Friday. Now they cannot stop talking about SMMT, even though these same news agencies have little understanding other than a superficial one, of how this company reached this level of market capitalization.

[Buckhenry]

If you look at the track record of these so called analyst... you loose that gitty feeling. They have have been projecting for years on this and just keep kicking the can down the road... but as they say... even a blind squirrel finds a nut once in a while...

[Noteable]

"blind squirrel finds a nut once in a while". And we can use Summit Therapeutics with a market cap of US$23.5 Billion as one good example of those nuts starting to fall into ONCY's sandbox.

[Buckhenry]

Just because some other companies have been bought out is not indicative that oncy will be bought. That is just stupid wishing which some on here have done for years. Taking a realistic view and laughing a little  along the way is a much better approach. Biotechs are obviously like playing the roulette wheel. You can be in phase 3 and just as the wheel stops it jumps to a different number and

[CMHarring218431]

Off topic Noone viewing Kamala's last interview can possibly come out and say the woman is qualified to run this country, let alone a variety store. Not one Democrat in office has spoken up to say anything since. She is absolutely clueless. She giggles and throws out useless dribble because she is not capable of speaking to a direct question of any sort. It is beyond my comprehension that

[13X2413]

Trump needs to save the pets in Springfield. I think that info may have come from Homer Simpson. 

[Noteable]

Summitt Therapeutics (SMMT) wasn't considered in anyone's wheelhouse in 2022 and today it boasts a market cap of $US 23 5 Billion. Go figure! 

[Noteable]

None of what venture00? said is true. For example, just last month ONCY entered into an open equity agreement with Cantor Fitzergerald and will be together with this financial institution at Cantor's Global Healthcare Conference next week in New York.

[Buckhenry]

I git all gitty in that special soft spot when I hear about oncy  fireside chats!!

[Angler101]

China and Russia are for the first time in history, conducting bi-lateral wargames in the Pacific, consisting of over 400 warships and over 120 aircraft.....does that tell you anything, Notable?....no?.....didn't think so.....

[Angler101]

China and Russia are, for the first time in history, conducting bi-lateral wargames in the Pacific, consisting of over 400 warships and over 120 aircraft.....does that tell you anything, Notable?.............I didn't think so.......

[Noteable]

Russia-China bi-lateral war games have nothing to do with China's intent to infiltrate and usurp the innovative  US biopharma and high technology industries.

[Angler101]

The Russia-China war games going on right now are merely a warm-up in anticipation of a continuation of the weak and feckless Biden-Harris "administration".....If Kamala Harris is elected "president", the infiltration of the biopharma and high tech industries, will be fully realized, along with every other aspect of our society, when China and Russia invade our weakened country

[Noteable]

Take your politics elsewhere. It has become worn in its conspiratorial dogma.

[Angler101]

Take MY politics elsewhere, Notable?.....oh, but you're allowed to post left-wing propoganda talking points like this that you posted out of the blue 2 days ago, when nobody had posted anything political on here for days?.. ...."Pandering, vanity, ego and the lack of character are best left for those in DJT's camp.". ...lol.....congrats at totally pointing out your own

[Noteable]

Yes Angler .. take your conspiratorial dogma and politics over to the same DJT 'cats and dogs' eating platform that you come from and support. 

[Angler101]

This post has been removed in accordance with Community Policy

[Noteable]

November 21, 2022 - Roche rival gets FDA priority review for CD3 bispecific https://www.fiercebiotech.com/biotech/abbvies-roche-rivaling-blood-cancer-bispecific-gets-fda-priority-review-triggering-payday Reovirus + CD3 bispecific combination .... "a true tumor-killer combo that would not be effective without each other." according to the investigators who undertook the bispecific

[Noteable]

A 15-month-old West Haven and Boston-based biotech wants to address T cell exclusion, when T cells can’t get into tumors, which is what ONCY is capable of doing with the pelareorep + CD3 bispecific antibody. https://endpts.com/pd-l1-pioneer-lieping-chen-rachel-humphrey-spin-out-new-biotech-to-break-down-the-door-on-cold-tumors/

[Noteable]

Repost: .. a true tumor-killer combo that would not be effective without each other. Both bispecific T-cell engagers and oncolytic viruses are promising cancer therapies, but the new research demonstrates that combining the two approaches could work even better. The researchers first administered oncolytic reovirus to both syngeneic murine and humanized tumor models, then injected the

[Noteable]

December 23, 2022 - The first CD20xCD3 bispecific antibody will soon become available in the US following an FDA approval disclosed Thursday night.   Roche and Genentech’s mosunetuzumab was greenlit as a third-line treatment for adults with relapsed or refractory follicular lymphoma. FDA’s accelerated approval of the therapy now branded as Lunsumio comes seven days early and follows suit

[Noteable]

Roche and Pfizer are both bispecitic players.

[Noteable]

If what the researchers are finding about pelareorep doesn't please the barking dogs on this message board, I'm not surprised since those doing the barking are more involved in the "trumped-up" antics of their disgraced leaders than in the reality of the effectiveness of ONCY's pelareorep .. but hey, stupid is still stupid no matter what good news the day brings.

[Noteable]

So now we can see why the addition of ONCY's pelareorep addition to multiple I/O cancer agents like bispecifics can turn most of those I/O combinations into a true-killer combination !! 

[Noteable]

Should read: - So now we can see why the addition of ONCY's pelareorep to multiple I/O cancer agents like bispecifics, can turn most of those I/O combinations into true-killer combinations !! 

[Noteable]

ONCY's synergy with bispecifics is even better than with anti-body drug conjugates (ADC) since ADCs are usually loaded with a chemotherapy agent while bispecifics are antibodies with two binding sites directed at two different antigens such as pelareorep + a CD3 surface antigen - which results in a more specific,, more effective and less toxic I/O agent than that of an ADC. More importantly

[Noteable]

More accurately, both Roche and Pfizer are developing CD3 bispecifics.

[Noteable]

Roche and Pfizer are developing CD3 bispecific antibodies, in which ONCY has demonstrated superior efficacy.

[Noteable]

 Both Roche and Pfizer are developing CD3 bispecifics.

[Noteable]

Aside from internal R&D efforts, Pfizer plans to find $25 billion in 2030 revenues through external business development. The company struck multiple midsized buyouts in 2022—including the purchases of Biohaven’s migraine franchise for US$11.6 Billion and sickle cell disease player Global Blood Therapeutics for US$54. Billion—and plans plenty more dealmaking, said Albert Bourla

[Noteable]

J&J’s first-in-class antibody Talvey (talquetamab-tgvs) is bispecific, binding to the CD3 receptor on the T cell surface to a receptor expressed on the myeloma cells to bring them together, allowing the body’s immune system to kill the cancer.  The accelerated approval was based on a Phase II study. An overall response rate of 73.6% was seen in patients with at least four

[Noteable]

Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy Oncolytic reovirus administration represents an effective strategy to induce a local interferon response and strong T-cell influx, thereby sensitizing the tumor microenvironment for subsequent CD3-bsAb therapy https://pubmed.ncbi.nlm.nih.gov/33082167/

[westcoast1000]

Noteable, I remember clearly when you first posted that pela and CD3 biospecific antibody treatment was a killer combo, quoting the authors of that paper. Your mention of J&J as a potential suitor for ONCY is intriquing. Given they want to build their pharma lines and that they are enthusiastic about CD-3 bsAb therapy, we could make an attractive target for them. Plus J&J could turn pela

[Buckhenry]

These forums  are full of ifs buts and maybes... and shoulda  coulda  woulda  statements....  and lots of brown nosers 

[Noteable]

Turning pelareorep into a standalone "brand" by a Big Pharma acquirer for use in multiple oncology disease states / cancers, is in line with pelareorep being considered an immune molecule platform technology that can be used as a platform drug in combination with multiple cancer drug therapies, such as CPIs, CD3 bispecifics, CAR-T, ADCs, and small molecules like PARP inhibitors, for

[Noteable]

January 31, 2024 - Pfizer drops  PF-07260437, a phase 1 therapy designed to treat advanced breast cancer, ovarian cancer or endometrial cancer. The B7-H4 x CD3 bispecific monoclonal antibody was intended to potentially help B7-H4 in favorably manipulating breast tumor immune microenvironment (TME), but was unable to achieve, and in which ONCY's pelareorep x CD3 has been

[Noteable]

Preconditioning the tumor microenvironment with oncolytic reovirus resulted in the activation of immunologically cold tumors,.This in turn led to more successful engagement of bispecific antibodies, causing tumor cell death. https://absoluteantibody.com/general/using-bispecific-antibody-reagents-to-further-research/

[Noteable]

Once again, Big Pharma is proving out pelareorep's benefits as a combination therapy through their continued clinical trial failures as monotherapies or in combination as bispecifics.

[Noteable]

As already posted ... ONCY's synergy with bispecifics is even better than with anti-body drug conjugates (ADC) since ADCs are usually loaded with a chemotherapy agent while bispecifics are antibodies with two binding sites directed at two different antigens such as pelareorep + a CD3 surface antigen - which results in a more specific,, more effective and less toxic I/O agent than that of

[Noteable]

Columvi is one of two bispecific antibody drugs that Roche recently introduced in the blood cancer space. The other Roche CD20xCD3 bispecific, Lunsumio, was approved in late 2022 to treat relapsed or refractory follicular lymphoma. https://www.fiercepharma.com/pharma/covid-windfall-rear-mirror-roche-starts-flesh-out-blood-cancer-ambition Like Roche, Pfizer is becoming 

[Noteable]

Repost .... Both bispecific T-cell engagers and oncolytic viruses are promising cancer therapies, but the new research demonstrates that combining the two approaches could work even better. The researchers first administered oncolytic reovirus to both syngeneic murine and humanized tumor models, then injected the CD3ε-bispecific antibodies. The combined treatment induced strong tumor

[Noteable]

https://stockhouse.com/companies/bullboard/oncy/oncolytics-biotech-inc?postid=36003899 https://www.sciencedirect.com/science/article/abs/pii/S0140673623005214

[Noteable]

.... a true tumor-killer combo that would not be effective without each other. Both bispecific T-cell engagers and oncolytic viruses are promising cancer therapies, but the new research demonstrates that combining the two approaches could work even better. The researchers first administered oncolytic reovirus to both syngeneic murine and humanized tumor models, then injected the CD3ε

[Noteable]

First posted here in September 2022 - when few knew about Summitt Therapeutics and SMMT was trading at US$1.29 per share .....  ONCY pelareorep + CD3 bispecific antibody true-killer combo.... a true tumor-killer combo that would not be effective without each other. Both bispecific T-cell engagers and oncolytic viruses are promising cancer therapies, but the new research demonstrates

[Noteable]

Today the CD3 protein is a hot target and the addition of ONCY's pelareorep to the CD3 bispecific potentiates the effectiveness of both agents due to improved T-cell quality from pelareorep's remodeling of the TME, and an appreciably improved T-cell infiltration, resulting in a greater effectiveness in the killing of the tumor cells.